Steris PLC

STERIS plc announced robust financial results for fiscal year 2026, with revenue up 9% and adjusted EPS increasing to $10.17, alongside a new $1 billion share repurchase program.

STERIS plc announced the appointment of Pierre Boulud to its Board of Directors, effective May 5, 2026, bringing extensive global leadership and strategic expertise.

STERIS plc announced an amendment to its transition agreement with former CFO Michael J. Tokich, extending his part-time senior financial advisor role through March 31, 2027, with adjusted compensation and benefits.

STERIS plc announced robust financial results for its fiscal 2026 third quarter, with total revenue up 9% and adjusted EPS increasing to $2.53, while reaffirming its full-year outlook.

STERIS plc reported strong fiscal 2026 second-quarter results, with total revenue up 10% and adjusted EPS increasing to $2.47, leading to an upward revision of its full-year financial guidance.

STERIS plc reported strong fiscal Q1 2026 results with revenue and EPS exceeding expectations, alongside a planned CFO transition and board updates.

STERIS plc reported robust financial performance for the third quarter and first nine months of fiscal 2026, driven by increased volume and pricing across all segments.

STERIS plc reports robust Q2 and H1 fiscal 2026 results with significant revenue and operating income growth across all segments, driven by volume and pricing.

STERIS plc reported robust first-quarter fiscal 2026 results with significant revenue growth, improved profitability, and strong cash flow, driven by all three segments and reduced debt.

STERIS plc announces a 5.6% increase in revenue for Q3 2025, driven by organic growth and strategic initiatives, including a restructuring plan to enhance profitability.

STERIS plc's second quarter of fiscal year 2025 saw a 7.3% increase in revenue, driven by the Healthcare segment, while the company progresses with its restructuring plan.

STERIS plc's first quarter fiscal 2025 results show revenue growth and a strategic restructuring plan aimed at enhancing profitability.

STERIS reports strong fiscal 2026 growth with revenues rising 8.7% to $5.94 billion, driven by volume and pricing gains.

STERIS plc announced a 6.2% increase in total revenues to $5.46 billion for fiscal year 2025, driven by robust performance in its Healthcare and Applied Sterilization Technologies segments, alongside a substantial reduction in debt after the sale of its Dental business.

STERIS plc's annual 10-K filing reveals a 13.3% revenue increase, strategic acquisitions, and a planned divestiture, alongside detailed financial results and risk factors.

Sohi Mohsen, a Director at STERIS plc, reported transactions involving ordinary shares and stock options on July 1, 2026.

John Adam Zangerle, Sr. VP, Gen Counsel, and Sec. of STERIS plc, reported a disposition of 1,419 ordinary shares on June 15, 2026.

John Adam Zangerle, Sr. VP, Gen Counsel, and Sec. of STERIS plc, reported a transaction involving the sale of 401 ordinary shares to cover tax withholding obligations.

Renato Tamaro, V.P. & Corporate Treasurer of STERIS plc, reported a transaction involving the withholding of shares for tax purposes upon vesting and provided an update on beneficial ownership.

STERIS plc reports that Sr. VP Julia Madsen disposed of 195 ordinary shares to cover tax obligations upon the vesting of restricted stock.

STERIS plc executive Kenneth E. Kohler reported a disposition of 150 ordinary shares on June 4, 2026, primarily to cover tax withholding obligations upon the vesting of restricted shares.

STERIS plc announces its 2026 Annual General Meeting of Shareholders, detailing proposals for director elections, auditor ratification, and executive compensation.

STERIS plc announced the retirement of Dr. Richard M. Steeves from its Board of Directors effective July 31, 2025, and his subsequent withdrawal from re-election at the upcoming Annual General Meeting.

STERIS plc has announced its Annual General Meeting for July 31, 2025, where shareholders will vote on the election of directors, auditor appointments, executive compensation, and share issuance authorities.

STERIS plc details its agenda for the 2025 Annual General Meeting, including director elections, auditor appointments, and proposals for share issuance authority, alongside reporting robust fiscal 2025 revenue growth and increased net income.

STERIS plc is holding its Annual General Meeting on August 1, 2024, and is encouraging shareholders to review proxy materials and vote on key proposals.

STERIS plc will hold its Annual General Meeting on August 1, 2024, in Dublin, Ireland, with shareholders voting on director elections, auditor ratification, executive compensation, and share issuance authorizations.

State Street Corporation has reported beneficial ownership of 5.1% of STERIS PLC's common stock as of March 31, 2026.

Vanguard Capital Management reports beneficial ownership of 7.48% of STERIS PLC's common stock as of March 31, 2026.

Vanguard Portfolio Management reports beneficial ownership of over 4.96 million shares, representing 5.05% of STERIS PLC's common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in STERIS PLC following an internal realignment, disaggregating its holdings.

Massachusetts Financial Services Company has reduced its beneficial ownership in STERIS PLC to 4.9%, falling below the 5% reporting threshold.